Bisindole-PBD regulates breast cancer cell proliferation via SIRT-p53 axis

References

• Rivera E, Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res 2010; 12 Suppl 2:S2; http://dx.doi.org/10.1186/bcr2573
   PubMed Web of Science ®Google Scholar
• Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer 2013:137414; PMID:23864953; http://dx.doi.org/10.1155/2013/137414
   PubMedGoogle Scholar
• van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LC. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 2009; 1; 27(4):542-9; PMID:19075277; http://dx.doi.org/10.1200/JCO.2008.17.1462
   PubMed Web of Science ®Google Scholar
• X Sui, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death and Disease 2013; Oct 10; 4:e838; PMID:24113172; http://dx.doi.org/10.1038/cddis.2013.350
   PubMed Web of Science ®Google Scholar
• Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008; 8(3):187-98; PMID:18473732; http://dx.doi.org/10.2174/156800908784293659
   PubMed Web of Science ®Google Scholar
• German S, Hafiz Muhammad Aslam, Shafaq Saleem, Aisha Raees, Alvi AA. Carcinogenesis of PIK3CA. Hered Cancer Clin Pract 2013; 11:5; PMID:23768168; http://dx.doi.org/10.1186/1897-4287-11-5
   PubMed Web of Science ®Google Scholar
• Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, Haupt Y, Hannan RD, Pearson RB. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene 2012; 31(15):1949-1962; PMID:21909130; http://dx.doi.org/10.1038/onc.2011.394
   PubMed Web of Science ®Google Scholar
• Saretzki G. Cellular senescence in the development and treatment of cancer. Curr Pharm Des 2010 Jan; 16(1):79-100; PMID:20214620; http://dx.doi.org/10.2174/138161210789941874
   PubMed Web of Science ®Google Scholar
• Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 2; 358(6381):15-6; PMID:1614522; http://dx.doi.org/10.1038/358015a0
   PubMed Web of Science ®Google Scholar
• Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996; 1287:77-102; PMID:8672531; http://dx.doi.org/10.1016/0304-419X(95)00019-C
   PubMed Web of Science ®Google Scholar
• Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10:1054-1072; PMID:8654922; http://dx.doi.org/10.1101/gad.10.9.1054
   PubMed Web of Science ®Google Scholar
• Fan S, Smith ML, Rivet DJ 2nd, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr, O'Connor PM. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 55:1649-1654; PMID:7712469
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108(2):153-64; PMID:11832206; http://dx.doi.org/10.1016/S0092-8674(02)00625-6
   PubMed Web of Science ®Google Scholar
• Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003; 15(2):164-71; PMID:12648672; http://dx.doi.org/10.1016/S0955-0674(03)00003-6
   PubMed Web of Science ®Google Scholar
• Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998; 281:1677-1679; PMID:9733515; http://dx.doi.org/10.1126/science.281.5383.1677
   PubMed Web of Science ®Google Scholar
• Amano T, Nakamizo A, Mishra SK, Gumin J, Shinojima N, Sawaya R, Lang FF. Simultaneous phosphorylation of p53 at serine 15 and 20 induces apoptosis in human glioma cells by increasing expression of pro-apoptotic genes. J Neurooncol 2009; 92(3):357-71; PMID:19357962; http://dx.doi.org/10.1007/s11060-009-9844-1
   PubMed Web of Science ®Google Scholar
• Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci USA 2004; Feb 24; 101(8):2259-64; PMID:14982997; http://dx.doi.org/10.1073/pnas.0308762101
   PubMed Web of Science ®Google Scholar
• Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res 2011; 71(5):1893-903; PMID:21245100; http://dx.doi.org/10.1158/0008-5472.CAN-10-2458
   PubMed Web of Science ®Google Scholar
• Groth A, Rocha W, Verreault A, Almouzni G. Chromatin challenges during DNA replication and repair. Cell 2007; 128(4):721-33; PMID:17320509; http://dx.doi.org/10.1016/j.cell.2007.01.030
   PubMed Web of Science ®Google Scholar
• Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37(4):391-400; PMID:15765097; http://dx.doi.org/10.1038/ng1531
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of Histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5(9):769-84; PMID:16955068; http://dx.doi.org/10.1038/nrd2133
   PubMed Web of Science ®Google Scholar
• Woan KV, Sahakian E, Sotomayor EM, Seto E, Villagra A. Modulation of antigen presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol 2012; Jan; 90(1):55-65; PMID:22105512; http://dx.doi.org/10.1038/icb.2011.96
   PubMed Web of Science ®Google Scholar
• Kai Li, Jianyuan Luo. The role of SIRT1 in tumorigenesis. N Am J Med Sci 2011; 4(2):104-106; PMID:22180829; http://dx.doi.org/10.7156/v4i2p104
   PubMedGoogle Scholar
• Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001;107(2):137-148; PMID:11672522; http://dx.doi.org/10.1016/S0092-8674(01)00524-4
   PubMed Web of Science ®Google Scholar
• Botta G, De Santis LP, Saladino R. Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins. Curr Med Chem 2012; 19(34):5871-84; PMID:22998567; http://dx.doi.org/10.2174/092986712804143303
   PubMed Web of Science ®Google Scholar
• Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao CD, Lam EW. SIRT inhibitors induce cell death and p53 acetylation through targeting SIRT1 and SIRT2. Mol Cancer Ther 2010; Apr; 9(4):844-55; PMID:20371709; http://dx.doi.org/10.1158/1535-7163.MCT-09-0971
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128(4):683-92; PMID:17320506; http://dx.doi.org/10.1016/j.cell.2007.01.029
   PubMed Web of Science ®Google Scholar
• Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000; 60(21):6039-44; PMID:11085525
   PubMed Web of Science ®Google Scholar
• Kamal A, Srikanth YV, Ramaiah MJ, Khan MN, Kashi Reddy M, Ashraf M, Lavanya A, Pushpavalli SN, Pal-Bhadra M. Synthesis, anticancer activity and apoptosis inducing ability of bisindole linked pyrrolo[2,1-c][1,4]benzodiazepine conjugates. Bioorg Med Chem Lett 2012; 22:571-8; PMID:22104151; http://dx.doi.org/10.1016/j.bmcl.2011.10.080
   PubMed Web of Science ®Google Scholar
• Sarma P, Ramaiah MJ, Kamal A, Bhadra U, Bhadra MP. A novel bisindole-PBD conjugate causes DNA damage induced apoptosis via inhibition of DNA repair pathway. Cancer Biol Ther 2014; 15(10):1320-32; PMID:25010292; http://dx.doi.org/10.4161/cbt.29705
   PubMed Web of Science ®Google Scholar
• Fröjdö S, Durand C, Molin L, Carey AL, El-Osta A, Kingwell BA, Febbraio MA, Solari F, Vidal H, Pirola L. Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1. Mol Cell Endocrinol 2011; Mar 30; 335(2):166-76; PMID:21241768; http://dx.doi.org/10.1016/j.mce.2011.01.008
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; Nov 16; 408(6810):307-10; PMID:11099028; http://dx.doi.org/10.1038/35042675
   PubMed Web of Science ®Google Scholar
• Igata E, Inoue T, Ohtani-Fujita N, Sowa Y, Tsujimoto Y, Sakai T. Molecular cloning and functional analysis of the murine bax gene promoter. Gene 1999; 238(2):407-15; PMID:10570968; http://dx.doi.org/10.1016/S0378-1119(99)00348-0
   PubMed Web of Science ®Google Scholar
• Bhuvanesh S, Reddy PG, Goberdhan A, Walsh C, Dao S, Ngai I, Chou TC, O-Charoenrat P, Levine AJ, Rao PH, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 2002; 16(8):984-993; PMID:11959846; http://dx.doi.org/10.1101/gad.973602
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci 2005; 102:8204-8209; PMID:15928081; http://dx.doi.org/10.1073/pnas.0502857102
   PubMed Web of Science ®Google Scholar
• Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, et al. The PI3 kinase/mTOR blocker NVPBEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat 2011; 129(2):387-400; PMID:21046231; http://dx.doi.org/10.1007/s10549-010-1232-1
   PubMed Web of Science ®Google Scholar
• McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 2010; 10 Suppl. 3:S59-65; PMID:21115423; http://dx.doi.org/10.3816/CBC.2010.s.013
   PubMedGoogle Scholar
• Trapp J, Jochum A, Meier R, Saunders L, Marshall B, Kunick C, Verdin E, Goekjian P, Sippl W, Jung M, et al. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem 2006; 49(25):7307-16; PMID:17149860; http://dx.doi.org/10.1021/jm060118b
   PubMed Web of Science ®Google Scholar
• Jin Q, Yan T, Ge X, Sun C, Shi X, Zhai Q. Cytoplasm-localized SIRT1 enhances apoptosis. J Cell Physiol 2007; 213(1):88-97; PMID:17516504; http://dx.doi.org/10.1177/1947601912475079
   PubMed Web of Science ®Google Scholar
• Zhenghong L, Deyu F. The roles of SIRT1 in cancer. Genes Cancer 2013; 4(3-4):97-104; PMID:24020000; http://dx.doi.org/10.1177/1947601912475079
   PubMedGoogle Scholar
• Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 2009; 5(2):147-52; PMID:19173036; http://dx.doi.org/10.7150/ijbs.5.147
   PubMed Web of Science ®Google Scholar
• Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, Pelicci PG, Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 2002; 21:2383-2396; PMID:12006491; http://dx.doi.org/10.1093/emboj/21.10.2383
   PubMed Web of Science ®Google Scholar
• Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107(2):137-48; PMID:11672522; http://dx.doi.org/10.1016/S0092-8674(01)00524-4
   PubMed Web of Science ®Google Scholar
• North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 2003; 11:437-44; PMID:12620231; http://dx.doi.org/10.1016/S1097-2765(03)00038-8
   PubMed Web of Science ®Google Scholar
• Brian JN, Eric V. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol 2004; 5(5):224; PMID:15128440; http://dx.doi.org/10.1186/gb-2004-5-5-224
   PubMed Web of Science ®Google Scholar
• Andreani A, Burnelli S, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Varoli L, Landi L, Prata C, Berridge MV, Grasso C Fiebig HH, Kelter G, Burger AM, Kunkel MW. Antitumor activity of bis-indole derivatives. J Med Chem 2008; 51(15):4563-70; PMID:18598018; http://dx.doi.org/10.1021/jm800194k
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9(10):1149-63; PMID:7758941; http://dx.doi.org/10.1101/gad.9.10.1149
   PubMed Web of Science ®Google Scholar
• Pandolfi PP. Transcription therapy for cancer. Oncogene 2001; 20(24):3116-27; PMID:11420728; http://dx.doi.org/10.1038/sj.onc.1204299
   PubMed Web of Science ®Google Scholar
• Minakshi N, Ahmad N, Wood GS. SIRT1 is upregulated in cutaneous T-cell lymphoma, and its inhibition induces growth arrest and apoptosis. Cell Cycle 2014; 13 (4); PMID:24343700; http://dx.doi.org/10.4161/cc.27523
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4(12):988-1004; PMID:16341064; http://dx.doi.org/10.1038/nrd1902
   PubMed Web of Science ®Google Scholar
• Chiang GG and Abraham RT. Targeting the mTOR signaling network in cancer. J Clin Oncol 2009; 27(13):2278-87; PMID:17905659; http://dx.doi.org/10.1200/JCO.2008.20.0766
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-1101; PMID:15718470; http://dx.doi.org/10.1126/science.1106148
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22; PMID:17613433; http://dx.doi.org/10.1016/j.ccr.2007.05.008
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3(6):415-28; PMID:12042769; http://dx.doi.org/10.1038/nrg816
   PubMed Web of Science ®Google Scholar
• Olmos Y, Brosens JJ, Lam EW. Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resist Updat 2011 Feb; 14 (1):35-44; PMID:21195657; http://dx.doi.org/10.1016/j.drup.2010.12.001
   PubMed Web of Science ®Google Scholar
• Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001 Oct 19; 107 (2):149-59; PMID:11672523; http://dx.doi.org/10.3410/f.1001553.2395457
   PubMed Web of Science ®Google Scholar
• Das C, Lucia MS, Hansen KC, Tyler JK. CBP/p300-mediated acetylation of histone H3 on lysine56. Nature 2009 May 7; 459 (7243):113-7; PMID:19270680; http://dx.doi.org/10.1038/nature07861
   PubMed Web of Science ®Google Scholar
• Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 2004 Oct 8; 16 (1):93-105; PMID:15469825; http://dx.doi.org/10.1016/j.molcel.2004.08.031
   PubMed Web of Science ®Google Scholar
• Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins - novel therapeutic targets to treat age associated diseases. Nat Rev Drug Discov 2008 Oct; 7(10):841-53; PMID:18827827; http://dx.doi.org/10.1038/nrd2665
   PubMed Web of Science ®Google Scholar
• Lain S, Lane D. Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer 2003 May; 39(8):1053-60; PMID:12736103, http://dx.doi.org/10.1016/S0959-8049(03)00063-7
   PubMed Web of Science ®Google Scholar
• Choi G, Lee J, Ji JY, Woo J, Kang NS, Cho SY, Kim HR, Ha JD, Han SY. Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects. Int J Oncol 2013 Oct; 43(4):1205-11; PMID:23900402; http://dx.doi.org/10.3892/ijo.2013.2035;
   PubMed Web of Science ®Google Scholar
• Ruthenburg AJ, Allis CD, Wysocka J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 2007; 25:15-30; PMID:17218268; http://dx.doi.org/10.1016/j.molcel.2006.12.014
   PubMed Web of Science ®Google Scholar
• Grewal SI, Jia S. Heterochromatin revisited. Nat Rev Genet 2007; 8(1):35-46; PMID:17173056; http://dx.doi.org/10.1038/nrg2008
   PubMed Web of Science ®Google Scholar
• Solomon JM, Pasupuleti R, Xu L, McDonagh T, Curtis R, DiStefano PS, Huber LJ. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 2006 Jan; 26(1):28-38; PMID:16354677; http://dx.doi.org/10.1128/MCB.26.1.28-38.2006
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zeng SX, Zhang Y, Zhang Y, Ding D, Ye Q, Meroueh SO, Lu H. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med 2012 Apr; 4(4):298-312; PMID:22331558; http://dx.doi.org/10.1002/emmm.201100211
   PubMed Web of Science ®Google Scholar